Antihypertensive drugs v placebo or other antihypertensive drugs for hypertension in type 2 diabetes*
| Outcomes | NRCTs (n) | Comparison | RRR (95% CI) | NNT (CI) |
|---|---|---|---|---|
| *NRCTs = number of randomised controlled trials. Abbreviations defined in glossary; RRR, NNT, and CI calculated from data in article. | ||||
| Total cardiovascular events | 1 (583) | Chlorthalidone plus atenolol or reserpine v placebo or usual care | 34% (6 to 54) | 13 (8 to 100) |
| 1 (492) | Nitrendipine v placebo | 62% (19 to 80) | 13 (8 to 34) | |
| 1 (3577) | Ramipril v placebo | 25% (12 to 36) | 20 (15 to 50) | |
| 1 (470) | Enalapril v nisoldipine | 57% (27 to 75) | 12 (8 to 25) | |
| 1 (380) | Fosinopril v amlodipine | 51% (5 to 74) | 15 (8 to 100) | |
| 1 (572) | Captopril v thiazide diuretic or β blocker | 41% (9 to 62) | Not reported | |
| 1 (1195) | Losartan v atenolol | 24% (2 to 42) | 20 (10 to 100) | |
| All cause mortality | 1 (3577) | Ramipril v placebo | 24% (8 to 27) | 34 (20 to 100) |
| 1 (572) | Captopril v thiazide diuretic or β blocker | 46% (4 to 69) | Not reported | |
| 1 (1195) | Losartan v atenolol | 39% (16 to 55) | 17 (10 to 50) | |
| Microvascular end points | 1 (3577) | Ramipril v placebo | 26% (1 to 29) | Not significant |
| 1 (1513) | Losartan v placebo | 21% (5 to 34) | Not significant | |
| 1 (590) | Irbesartan v placebo | 70% (39 to 86) | 10 (7 to 25) | |
| 1 (1715) | Irbesartan v amlopidine | 23% (7 to 37) | 12 (8 to 34) | |
